Fibrillary Glomerulonephritis Clinical Trial
Official title:
A Single-Center Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT02197767 -
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
|
Phase 2 | |
Active, not recruiting |
NCT05546047 -
A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients
|
Phase 4 |